This article is mentioned in:

Lynch syndrome: An overview

Clinical features

Lynch syndrome (LS) is the most common hereditary form of colorectal cancer (CRC) with an incidence of 3–5% of all CRC, followed by Familial Adenomatous Polyposis (FAP), which accounts for less than 1% of the total CRC. LS and FAP are autosomal dominant inheritance diseases, caused by germline mutations in the DNA mismatch repair (MMR) genes and the tumor suppressor gene Adenomatous Polyposis Coli (APC), respectively (1–2). LS is also known as hereditary non-polyposis colorectal cancer (HNPCC) to highlight the absence of colon polyps and to distinguish this syndrome from FAP characterized by 100–1,000 polyps (1–4) and other hereditary syndrome of colorectal cancer, such as hamartomatous polyposis syndrome (5–7). LS patients born with a germline mutation in one of these MMR genes, and acquire inactivation of the second wild-type allele in their tumoral DNA, fulfilling Knudson's two hit hypothesis for inactivation of tumor suppressor genes. The somatic inactivation of the corresponding wild-type allele occurs almost exclusively by small mutations or (partial) gene loss, and bi-allelic inactivation then leads to complete abolition of the protein function of MMR system (3). This results in a defective DNA MMR system. LS is characterized by a high lifetime risk for tumor development, especially in the case of CRC (20–70% with average age at diagnosis 44–61), endometrial cancer (15–70% with average age at diagnosis 48–62), gastric cancer (6–13% with average age at diagnosis 56), ovarian cancer (4–12% with average age at diagnosis 42,5) and other extracolonic tumors (total risk 15%) as small intestine, brain, skin hepatobiliary and urinary tract (1). Other phenotypic features of LS subjects are preferential tumor localization in the right-sided colon, presence of multiple synchronous and metachronous colorectal cancers, poorly differentiated tumors, with a marked lymphocytic peritumoral inflammation recalling features of so-called ‘Crohn's reaction’ and Microsatellite instability at somatic level (8,9).

Genetic bases

LS patients present with a germline mutation in one of the MMR genes, MLH1 on chromosome 3p21, MSH2 on chromosome 2p16, MSH6 on chromosome 2p16, PMS2 on chromosome 7p22, MLH3 on chromosome 2p16 and MSH3 on chromosome 5q11. The heteroduplex MutSα that predominantly identifies single base mispairings is formed by MSH2 and MSH6 proteins, while MSH2 with MSH3 form the MutSβ identifying short insertions or deletions. imilar, the MutLα and MutLγ subunits are formed by MLH1-PMS2 and MLH1-MLH3, respectively, they interacts with the MutSα or MutSβ complex, stimulating excision and resynthesis of abnormal DNA (10). MSH2 and MLH1 are, thus essential for both complexes to function. Therefore, the MMR genes, MLH1 and MSH2 are defined as ‘major’ MMR genes, while the MSH6, PMS2, MLH3 and MSH3 are known as ‘minor’ MMR genes (9). Somatic inactivation of the corresponding wild-type allele occurs almost exclusively through point mutations or (partial) gene loss; bi-allelic inactivation then leads to complete abolition of the protein function. This results in a defective DNA MMR system, since MMR proteins are involved in the correction of single nucleotide mismatches and small insertions or deletions that may arise during DNA replication (11). The absence of redundant functions for MSH2 and MLH1 proteins underlies the importance of these two genes in MMR complex. Majority of mutations was found in these genes (84 and 71% respectively). Carriers of MSH2 variants show a higher incidence of extracolonic malignancy (48–61%; endometrial, gastric, ovarian and kidney cancer) than the carrier of MLH1 variants (11–42%) (12). Regard to minor genes, the MSH6 variants, until a few years ago, seemed to cause a form of ‘attenuated’ LS (13), PMS2 variants were associated with combined presence of multiple colorectal adenomas and glioblastomas (14). Recently, also mutations in MLH3 gene have been associated with brain tumors (15). MSH3 variants were associated with a classic phenotype only if they were inherited in combination with MSH2 variants (16). Recently, it was showed that biallelic mutations in MSH3 gene are causing polyposis forms similar to FAP phenotype (17). Sometimes costitutional MLH1 methylation in the LS adenomas could represent the initiation of these neoplasms and it may present as a defect that was inherited (18).

Microsatellite instability of related-LS tumors

The deficiency of MMR complex determines high rate of mutations in repetitive DNA sequences known as microsatellites. This condition is known as microsatellite instability (MSI) and is present in approximately 95% of all LS-associated cancers (18). Many genes contain repetitive sequences in their coding regions and some of these have an important role in the regulation of cell growth (19). In fact, mutations in the TGFβRII and TCF−4 genes, that normally inhibit cell growth, and in the IGF-RII and BAX genes involved in the apoptotic process (20) particularly predispose to colon cancer. Moreover, the presence of polyadenine traits in the coding sequences of the minor MMR genes, MSH6, MLH3 and MSH3, makes the same MMR genes targets of the MSI phenotype (21,22).

The sporadic CRC also display an MSI phenotype in about 15%. In this case, the MSI may be result of somatic hypermethylation of the MLH1 gene promoter. The hypermethylation at the promoter of MLH1 allele lead to silencing expression from that allele in all main somatic tissues. In 40–87% of all sporadic microsatellite unstable tumors (23) with hypermethylation of the MLH1gene is present a specific mutation in the BRAF oncogene, usually the V600E missense mutation. This mutation is not present in LS MSI tumors in which the MSI phenotype is due to genetic alteration of MMR genes and it is not depend by epimutation (24).

Finally, another type of instability, ‘elevated microsatellite alterations at selected tetranucleotide repeats’ (EMAST), has also been identified in colon cancers. EMAST has been associated with both MSI. One known cause of EMAST is a deficiency or dysfunction of MSH3, which is required in the repair of tetranucleotide repeat mismatches in complex with MSH2. The MSH3 defect may also cause an impairment of homologous repair and increase sensitivity to some targeted therapies, such as poly (ADP-ribose) polymerase 1 (PARP1) inhibitors (25).

Clinical diagnosis and molecular analysis of Lynch syndrome

Clinical criteria

Identification of families affected by LS occurs by the Amsterdam Criteria (AC) and Bethesda guidelines. The clinical criteria of Amsterdam were used to identify families eligible for molecular analysis since 1990 (26). Subsequently, these criteria were modified, the AC II in order to include the other LS-related cancers (27). The Bethesda guidelines, which were less restrictive than AC, were later defined (28) and take into account the MSI-status detected at tumoral tissue. The ‘Panel of Bethesda’ recommended by the National Cancer Institute include five microsatellites: two mononucleotide repeats (BAT25, BAT26) and three dinucleotide repeats (D2S123, D17S250, D5S346) (29) that are analyzed on tumoral DNA of patients with likely LS. If at least two of these repeats (40% of markers) are instability, tumoral DNA shows high instability (MSI-H), while if at least 10–30% of markers are instability, tumoral DNA shows low instability (MSI-L); when no microsatellite is instable, tumoral DNA shows stability of microsatellite sequences (MSS) (30). Subsequently, other microsatellite sequences were included in the panel test: NR21, NR22 and NR24, quasimonomorphic mononuceotide repeats in order to improve the sensitivity rate and predictive specificity of Bethesda guidelines (31,32); these three repeats (NR21, NR22 and NR24) with BAT25 and BAT26 constitute the Pentaplex Panel (31).

Molecular analysis

LS is associated with mutations in MMR genes. Most of mutations were found in the MLH1 and MSH2 genes that account for about 50 and 40% respectively of all mutations reported; about 15–20% of mutations were identified in the MSH6 and in PMS2 (33,34); few pathogenetic mutations were identified in MLH3 (15) gene and so far, only one heterozygous variant in MSH3 gene was associated with LS phenotype (16). The most pathogenetic variants in MMR genes are small insertions/deletions or large genetic rearrangements (large deletions/insertions) that, at protein level, result in premature stop codon formation (35,36). Moreover, several mutations identified in MMR genes are missense, silent or intronic variants. The influence of these variants on the development of cancer is often a controversial topic; therefore, they are each classified as a variant of uncertain significance (VUS) (37). According to international recommandetions (Colon cancer Family Registry 2009, InSiGHT Variant Interpretation Committee 2011) it is possible to use a multifactorial likelihood model in an attempt to define a pathogenetic role of VUS (38). This approach is based on the evaluation of both phenotipic and functional features (9,39). In particular, the segregation analysis should be considered the ‘gold standard’ for the validation of VUS pathogenecity (34,39).

The loss of function of one MMR protein prevents to repair's complex to work properly and this determines a genetic instability known as MSI at somatic level (27).

The molecular analysis to make diagnosis of LS begins with the evaluation of the MSI status on tumoral DNA (see above) by DNA fragment analysis using capillary electrophoresis (38). At somatic level the MSI is detectable by immunohistochemistry (IHC) analysis (40). Instead, the common methods for the mutation detection analysis of MMR genes include the use of denaturing high-performance liquid chromatography (DHPLC) and direct sequencing for point mutations, and multiplex ligation-dependent probe amplification (MLPA) for large rearrangements (16,35,36). So far, a large number of variants in Insight-group Database (www.insightgroup.org) have been reported in MMR genes, in particular MLH1, MSH2, MSH6 and PMS2, Table I, while no variants in the MLH3 and MSH3 genes have been reported. However, literature data show cases of patients with hereditary colorectal cancer and with mutations in these two genes (15,16).

Table I. Numbers of genetic variants identified in MMR genes.

Table I.

Numbers of genetic variants identified in MMR genes.

Gene	Accession number	Total no. of genetic variants
MLH1	NM_000249.3	8,023
MSH2	NM_000251.2	6,346
MSH6	NM_000179.2	2,297
PMS2	NM_000535.5	1,264

[i] All data were retrived from the Insight Database.

Today, high-throughput techniques, such as next generation sequencing, have been substituted for these methods to allow the identification of a major number of genes involved in such hereditary cancer forms. For example, recent findings suggested POLE and POLD1 mutations are associated with gastrointestinal malignancies, with mutations in these genes having been identified in subjects with a Lynch-like phenotype (41).

Recent discoveries in molecular genetics of Lynch syndrome

New roles for MMR proteins

It is known a long time that MMR proteins have developed various other functions in addition to the postreplicative repair. Among these new roles (such as prevention of reparative recombination, promotion of meiotic crossover, expansion of repeated triplets, modulation of microRNA biogenesis) is included the immunoglobulin (Ig) diversification based on the ‘somatic hypermutation’ (SHM) process. This process is regulated by the MutSα -MutLα complex, in combination with two other proteins, AID (activation-induced cytidine deaminase) and Polµ (DNA Polymerase ‘error-prone’) (42); in particular, MutSα deficiency is associated with neoplastic transformation of T lymphocytes (43). Paradoxically, MMR maintains stability throughout the genome but is responsible for up to 60% of the mutations in V and S regions of the Ig locus that are important for diversification antibodies (44). Therefore, a better understanding of the intricate signaling cascades that govern antibody diversification could help uncover the associations between the maintenance of genomic integrity and tumorigenesis in the adaptive immune response.

Immune-response in LS colorectal cancer

LS cancers are usually referred to as MSI-H or MSI and conceptually display a very interesting biology and clinical behavior that is governed by the underlying mutational mechanism of these tumors. MMR-deficient cells accumulate an abundance of mutations at coding microsatellites, also found in tumor-relevant genes. These mutations may give rise to a loss of function of the respective proteins but may also trigger the translation of highly immunogenic frameshift neo-peptides or -antigens (FSPs) (45). Such FSP antigens may be shared if they occur in genes for which the mutational inactivation has a growth-promoting impact that is supportive for the development of a neoplasm. Such shared antigens may thus occur in multiple and independently arising MMR-deficient tumors. FSP neo-antigens are highly immunogenic due to long mutational antigens that encompass multiple potential epitopes (46). As these FSPs are derived from real shifts of the reading frame of the respective gene, they usually have a completely novel, and for the affected organism, foreign amino acid sequence, that results from insertions or deletions of single, individual nucleotides that alter the reading frame of the affected genes (Fig. 1). Such frame-shift mutations therefore generated substantially more immunogenic antigens in comparison, for example, to single missense mutations as they, for example, frequently occur in mutant P53 or KRAS genes. If one considers MMR deficiency as a unique mechanism of carcinogenesis, one can imagine that at the beginning of the carcinogenic process cell clones are generated that acquire mutations in coding microsatellites on a more random basis. Only cells in which the mutational spectrum favours neoplastic growth features will survive and further expand, whereas other cells with less favourable mutational spectra will be lost. Over time, this mechanism drives and shapes the mutational spectrum of the surviving cell clones into a better and better adapted status for local growth requirements. Thus, loss of the MMR system could represent an efficient mutational mechanism allows for a Darwinian selection process of carcinogenesis. The extensive generation of these neo-antigens in MSI cancers explains the pathological finding that MSI cancers are characterized by massive infiltration of lymphocytes and other immune-related cells that point to the strong immunogenicity of such cancers. MSI cancer cells can grow out to clinically manifest cancers if local T cells in their environment become exhausted. Alternatively, MSI cancer cells that have undergone immune evasion due to a loss of HLA-mediated antigen presentation may grow out irrespective of local T cell surveillance (47). Indeed, direct and indirect molecular mechanisms do not structurally interfere with the tumor cells' capacity to present FSP neoantigens, but influence the T cell activation status. In approximately 30% LS tumoral tissue mutation-induced loss of Beta 2 Microglobulin (B2M), the essential light chain of HLA class I antigens, induces a complete lack of assembled HLA class I antigens on the tumor cell surface. As a consequence, CD8-positive T cells cannot attack B2M-mutant LS cancer cells. Even mutations of the genes CIITA and RFX5, which are required for functional HLA class II antigen expression on the tumor cell surface, are found in up to 20% of MSI colorectal cancers and associated with a complete loss of HLA class II antigens on the tumor cell surface, consequently the inactivation of CD4-positive T cell (48). This may justify an endogenous immune antitumor response, counterbalanced by the expression of inhibitory immune signals, such as PD-1 binding to the PD-L1 receptor present on the lymphocyte membrane, inhibiting its production (Fig. 2). Immune checkpoints play a key role in limiting antitumor immunologic responses, such as those directed against cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) receptor and its ligand, PD-L. The ligation of T-cell PD-1 by the tumor results in the downregulation of T-cell effector functions that can destroy tumor tissue. Therefore, the blockade of this pathway by anti-PD-1 antibodies prevents this downregulation, and allows T cells to maintain their antitumor functionality and ability to mediate tumor cell death (48,49).

Figure 1. Mismatch repair-deficient cells accumulate an abundance of mutations at coding microsatellites that may give rise to a loss of function of the respective proteins; however, may additionally trigger the translation of highly immunogenic FSPs or -antigens. FSP, frameshift neo-peptide.

Figure 2. In tumoral cells, the ligation of T-cell PD-1 results in the downregulation of T-cell (CD8+ and CD4+) effector functions that may destroy tumor tissue; this downregulation of T-cell may favor the neoplastic expansion. PD-1, programmed cell death-1; FSP, frameshift neo-peptide.

Management of Lynch syndrome patient with CRC

The early detection of LS-mediated CRC progression

To improve the quality of care of patients and families with any hereditary condition resulting in gastrointestinal tumours as Lynch syndrome is the identification of carriers of relevant predisposition alleles (50). The purpose of this is reducing MMR associated hereditary colorectal cancer mortality. It is known a long time that carrier subjects of pathogenetic mutation in a MMR gene undergone to recommends annual surveillance colonoscopy from age 25 years (51). In order to include the mutation carriers in the endoscopy surveillance programs more suited to them, a crucial point is represented by correct definition of the pathogenecity of MMR genetic variants identified in the mutation detection analysis (52,53). Thus, this knowledge may helpful to improve the related-LS cancer prevention programs. Recently, MSH6 and PMS2 mutation carriers have been reported to have a lower risk of CRC with a later age of presentation (54). Indeed, literature data support a move to commence colonoscopy surveillance in MSH6 and PMS2 mutation carriers at the older age of 30 years, providing no young index CRC, and extend the interval to 2 years (55). Therefore, the classification of MMR genetic variants is many important to choose the most appropriate endoscopic surveillance program and to precede towards a personalized medicine (56) (Fig. 3).

Figure 3. Management of patients with Lynch syndrome.

Therapeutic approaches of LS-related colon cancer

The choose of the optimal treatment approach for patients with metastatic colorectal cancer is based on evaluation of clinical and genomic features of tumors. It is important to take into account of the side of the colon in which the primary tumor originates, the sites and burden of metastatic disease, by mutational status of some genes, as KRAS, BRAF (57) and the MSI status on tumoral DNA (58). The most applied protocol of adjuvant chemotherapy for colorectal cancer not metastatic (stage II) involves the administration of 5-fluorouracil (5FU). Instead in some metastatic CRC cases (stage III), systemic therapy with a FOLFOX- or CAPOX (capecitabine and oxaliplatin) regimen is the standard of care in these patients. Patients with left-sided and RAS wild-type tumors receive anti-epidermal growth factor receptor (EGFR)-directed therapy, while patients with right-sided tumors or those with RAS mutations receiving bevacizumab (59). In patients with tumors that manifest microsatellite instability or deficient mismatch repair, adjuvant chemotherapy with 5-fluorouracil did not result in a survival benefit in subgroup analyses of patients with colon cancer without metastasis. While, among patients with metastatic colon cancer who received the treatment with capecitabine and oxaliplatin, survival was significantly longer among those who had deficient mismatch repair than among those who had proficient mismatch repair.

These different features are probably related to the lymphocytic infiltrate characteristic of MMR-deficient tumors that determines an antitumor immune response that may be abrogated by the immunosuppressive effects of chemotherapy (60). Despite this enhanced immunogenicity, T cells are unable to eradicate these tumors, likely due to overexpression of immune checkpoint proteins that can be antagonized by checkpoint inhibitors (Fig. 2). Recently, immune checkpoint-inhibiting agents have been developed as antitumor drugs and appear promising, especially in sporadic CRC patients with MSI. Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between PD-1 on T-cells, and PD-L1 and PD-L2 on tumor cells. The antibody pembrolizumab has been evaluated in patients with metastatic colorectal cancer and MSI in whom previous treatment with cytotoxic agents had failed. The response to treatment was similar in patients with LS-related CRC and those sporadic CRC. Moreover, the combination of nivolumab, another anti-PD-1 antibody, plus ipilimumab, an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody, resulted in response rates and disease-control rates that were higher than those previously reported with nivolumab alone (61). In this context, it is interesting to note that this drugs show good results in the treatment of tumors with MSI (Fig. 3).

Conclusions

Identifying the mutation that causes clinical manifestations of Lynch syndrome is crucial given the relatively early onset of the disease, the high penetrance of mutations, as well as the proven efficiency of surveillance strategies. Furthermore, the studies carried out over the years on the molecular mechanisms underlying the onset of LS-related colorectal cancer have allowed us to make significant advances also in the therapeutic treatments of these tumors. Recently, immune checkpoint-inhibiting agents have been developed as antitumor drugs and appear promising, especially in sporadic CRC patients with MSI. Precisely because the subjects with Lynch syndrome show in 95% of cases MSI-H on the tumor tissue, we could say that they are ideal candidates for immunotherapeutic treatment. Finally, we hope in the near future in the context of this research will be possible to establish a preventive cancer vaccine for Lynch syndrome as recently reported by studies on the preclinical mouse model (62) (Fig. 3).

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

Not applicable.

Authors' contributions

FD and PI designed the review. RL and MDR preformed the literature search. FD and PI interpreted the scientific articles, and FD wrote the first draft of the manuscript. FD developed the structure of the paper and the discussion. RL, MDR and PI critically revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References